AbelZeta Receives RMAT Designation for C-CAR168 for the Treatment of Refractory SLE, Including LN

C-CAR168 is a novel autologous bi-specific CAR-T therapy targeting both CD20 and B-cell maturation antigens (BCMA) in the treatment of patients with autoimmune diseases The post AbelZeta Receives RMAT Designation for C-CAR168 for the Treatment of Refractory SLE, Including LN appeared first on AbelZeta Pharma .